Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from BeiGene Ltd ( (HK:6160) ).
BeiGene Ltd. announced that the U.S. Patent and Trademark Office has invalidated all claims of a Pharmacyclics LLC patent that were challenged by BeiGene in a post-grant review proceeding. This decision, which can be appealed by Pharmacyclics, comes after a patent infringement lawsuit was filed against BeiGene concerning its cancer treatment drug, BRUKINSA (zanubrutinib). The ruling potentially strengthens BeiGene’s position in the oncology market by removing a legal obstacle related to its product.
More about BeiGene Ltd
BeiGene Ltd. is a biotechnology company focused on developing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company operates globally, with a significant presence in the U.S. and China, and is dedicated to improving treatment outcomes for cancer patients worldwide.
YTD Price Performance: 34.34%
Average Trading Volume: 5,634,043
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$218.8B
For an in-depth examination of 6160 stock, go to TipRanks’ Stock Analysis page.